Dividend Roundup: Starbucks, Pfizer, Micron, AbbVie, and more:
Weekly dividend roundup: RPM & Starbucks raise payouts, Pfizer and AGNC declare dividends ...
seekingalpha.com/news/4651667-dividend-roundup-starbucks-pfizer-micron-abbvie-and-more
Paid articlePaywallStory Details
| Last Updated | |
| Total Articles | 1 |
Main Topics
Similar to This
Previous
Zepbound grew 174.9% in 2025, the fastest rate among the top 10 drugs: Seven of the best-selling drugs of 2026 from GEN's top 10, ranked by 2025 sales ...
qz.com/best-selling-drugs-2026-2025-sales
MASH in the Modern Era: This educational initiative gives clinicians the tools they need to manage MASH in the modern era.
medscape.org/advances/mash-modern-era-2026a10007jk
MASH in the Modern Era: This educational initiative gives clinicians the tools they need to manage MASH in the modern era.
medscape.org/advances/mash-modern-era-2026a10007jk
Starbucks CEO gets roasted for $9 ‘premium experience’ remarks, but Wall Street toasts his tariff-era turnaround strategy
fortune.com/2026/05/04/starbucks-ceo-roasted-9dollar-coffee-premium-wall-street-earnings/
Paid articlePaywallBrian Niccol’s nascent Starbucks turnaround starts with treating workers better: Also: All the news and watercooler chat from Fortune.
fortune.com/2026/05/01/starbucks-turnaround-brian-niccol-ceo-workers/
Paid articlePaywallStarbucks is winning customers back after investing $500 million in workers and stores
fortune.com/2026/04/29/starbucks-coo-turnaround-workers-baristas-stores-pay-benefits/
Paid articlePaywall
CNBC Apr 29
Starbucks CEO Brian Niccol: Working to see how we can be sharper on cost side of things
cnbc.com/video/2026/04/29/starbucks-ceo-brian-niccol-working-to-see-how-we-can-be-sharper-on-cost-side-of-things.html
STAT Feb 24
New treatment approach could give IBD patients hope, and be a bonanza for drugmakers
statnews.com/2026/02/24/ibd-combination-therapy-race-abbvie-lilly-pfizer-merck-jnj/
Paid articlePaywall Next